ADJ-102 for the Treatment of Solid Tumor

Overview

Drug Name	ADJ-102
Description	ADJ-102 is a prodrug of the topoisomerase I-inhibiting product chimmitecan. The product is in early clinical trials as a treatment for patients with advanced solid tumors.
Target	DNA Topoisomerase I
Drug Modality	Small Molecule
Indication	Solid Tumor
Product Category	Camptothecins
Mechanism of Action	DNA Topoisomerase I Inhibitors
Status	Clinical Trial
Patent	Granted

Seeking Global Cooperation

Protheragen Inc. is actively seeking partnership for ADJ-102. Potential collaboration can be strategic alliance, licensing, or marketing agreement.
We look forward to hearing from you.

Target

DNA Topoisomerase I

This gene encodes a DNA topoisomerase, an enzyme that controls and alters the topologic states of DNA during transcription. This enzyme catalyzes the transient breaking and rejoining of a single strand of DNA which allows the strands to pass through one another, thus altering the topology of DNA. This gene is localized to chromosome 20 and has pseudogenes which reside on chromosomes 1 and 22.

E-mail: inquiry@protheragen.com

www.protheragen.com

101-4 Colin Dr, Holbrook, NY 11741, USA

Indication

Solid Tumor

Solid tumors are abnormal mass of tissue that usually does not contain cysts or liquid areas. Solid tumors may be benign or malignant. Different types of solid tumors are named for the type of cells that form them, such as breast cancer. Based on projections, cancer deaths will continue to rise with an estimated 11.4 million people dying from cancer in 2030.

The best strategy for fighting cancer is prevention to reduce cancer risk. Nevertheless, even if we were to apply all that we know about preventing cancer, one out of four cancers would still occur. Because of this, therapies that target malignancies after they have developed will continue to be important for some time to come. The most commonly used treatment modalities of cancer include some combination of surgery, radiation therapy, and chemotherapy. The best approach to treating cancer provides a balance between therapeutic effectiveness and minimization of treatment-associated side effects.

The global market for solid tumor treatment was estimated at $121.3 billion in 2018 and is expected to reach $424.6 billion by 2027, expanding at a CAGR of 15% from 2019 to 2027.

Mechanism of Action

DNA Topoisomerase I Inhibitors

Molecular Mechanism	Drugs Targeting DNA Topoisomerase I

E-mail: inquiry@protheragen.com

www.protheragen.com

101-4 Colin Dr, Holbrook, NY 11741, USA

Status

The Status of ADJ-102

The international patent applications under the PCT have been granted.

	Discovery/Optimization	Preclinical	Clinical
ADJ-102			

E-mail: inquiry@protheragen.com

www.protheragen.com

101-4 Colin Dr, Holbrook, NY 11741, USA